Clinical trials: Post-traumatic Stress Disorder (PTSD)
- Condition Post-traumatic Stress Disorder (PTSD)
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Posttraumatic Stress Disorder
MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD
The goal of this clinical trial is to learn if cognitive-behavioral conjoint therapy (CBCT) in combination with MDMA-assisted therapy is safe and effective in people with chronic PTSD and their partners.
- Trial name
- NCT02876172
- Testing
- MDMA, CBCT, Therapy
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Resilient Pharmaceuticals
Obstructive Sleep Apnea (OSA), Post-Traumatic Stress Disorder (PTSD)
Comparison Study Using APAP With and Without SensAwake in Patients With OSA and PTSD
The purpose of this research is to examine the application of AutoCPAP with and without SensAwake in subjects with OSA and Post-Traumatic Stress Disorder (PTSD), and evaluate whether patients achieve better sleep quality and…
- Trial name
- NCT02549508
- Testing
- AutoCPAP with SensAwake On, AutoCPAP with SensAwake Off
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Fisher and Paykel Healthcare
Post Traumatic Stress Disorder
Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD
This will be a 12-week, multicenter, randomized, double-blind trial evaluating the efficacy, safety, and tolerability of brexpiprazole + sertraline combination treatment in adult participants with Post-Traumatic Stress Disorder.
- Trial name
- NCT04124614
- Testing
- Brexpiprazole, Sertraline
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Post Traumatic Stress Disorder
A Study to Assess the Use of Methylone in the Treatment of PTSD
This study is evaluating the safety, tolerability, and efficacy of methylone in adults with PTSD. The study will be conducted in two parts.
- Trial name
- IMPACT-1 (NCT05741710)
- Testing
- Methylone
- Where
- 16 sites in United States, Ireland and 1 more
- Volunteers
- 79 people
- Sponsor
- Transcend Therapeutics
Post-Traumatic Stress Disorder
A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)
The purpose of this study is to assess the effects of BNC210 compared to placebo on Post-Traumatic Stress Disorder (PTSD) symptom severity as measured by the Clinician Administered PTSD scale for The Diagnostic and Statistical…
- Trial name
- ATTUNE (NCT04951076)
- Testing
- BNC210
- Where
- 32 sites in United States, United Kingdom
- Volunteers
- 212 people
- Sponsor
- Bionomics Limited
Post Traumatic Stress Disorder
An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD
This study is evaluating the safety and efficacy of methylone in adults with PTSD. The study is conducted in two parts. Part A is open-label and will enroll up to 15 participants with PTSD Part B is randomized (1:1:1)…
- Trial name
- IMPACT-2 (NCT06215261)
- Testing
- Methylone
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 62 people
- Sponsor
- Transcend Therapeutics
Post-Traumatic Stress Disorder, Stress Disorders, Post-Traumatic
Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD)
This is a single-blind, placebo-controlled, parallel group study to evaluate the efficacy of BRL29060A (paroxetine hydrochloride hydrate, hereafter paroxetine) administered orally over the dose range of 20 mg to 50 mg once daily…
- Trial name
- NCT00557622
- Testing
- paroxetine
- Where
- 9 sites in Japan
- Volunteers
- 5 people
- Sponsor
- GlaxoSmithKline
PTSD
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study that will investigate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) - a sublingual formulation of cyclobenzaprine.
- Trial name
- RECOVERY (NCT03841773)
- Testing
- TNX-102 SL
- Where
- 30 sites in United States
- Volunteers
- 192 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
PTSD
A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective at reducing PTSD symptoms in people with PTSD who received placebo in a prior MDMA-assisted therapy study.
- Trial name
- MAPPUSX (NCT04714359)
- Testing
- Midomafetamine HCl
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 87 people
- Sponsor
- Resilient Pharmaceuticals
PTSD
Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD
The goal of this clinical trial is to learn if MDMA-assisted therapy is effective in U.S. military veterans with at least moderate chronic PTSD.
- Trial name
- MPVA6 (NCT04784143)
- Testing
- Midomafetamine, Psychotherapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Resilient Pharmaceuticals
PTSD
Ganaxolone in Posttraumatic Stress Disorder (PTSD)
This Phase 2 proof-of-concept study is a double-blind, randomized, placebo-controlled, 15-week investigation of ganaxolone versus placebo for the treatment of Posttraumatic Stress Disorder (PTSD).
- Trial name
- NCT01339689
- Testing
- Ganaxolone
- Where
- 8 sites in United States
- Volunteers
- 112 people
- Sponsor
- Marinus Pharmaceuticals
Post Traumatic Stress Disorder
A Study of JZP150 in Adults With Posttraumatic Stress Disorder
This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP150 in the treatment of adult participants with post-traumatic stress disorder (PTSD).
- Trial name
- NCT05178316
- Testing
- JZP150
- Where
- 52 sites in United States
- Volunteers
- 282 people
- Sponsor
- Jazz Pharmaceuticals
PTSD
Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study that will investigate the efficacy and safety of two doses of TNX-102 SL -a sublingual formulation of cyclobenzaprine.
- Trial name
- AtEase (NCT02277704)
- Testing
- TNX-102 SL
- Where
- 23 sites in United States
- Volunteers
- 245 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
PTSD
Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions
This is a 12-week, multicenter, open-label extension study to evaluate the safety and efficacy of TNX-102 SL tablet taken daily at bedtime in patients with Military-Related PTSD or related condition.
- Trial name
- P202 (NCT02421679)
- Testing
- TNX-102 SL
- Where
- 22 sites in United States
- Volunteers
- 159 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
PTSD
12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients
This is an open-label, extension trial designed to evaluate safety over 12 additional weeks of TNX-102 SL therapy taken daily at bedtime for the treatment of PTSD.
- Trial name
- NCT03110575
- Testing
- TNX-102 SL
- Where
- 32 sites in United States
- Volunteers
- 190 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Posttraumatic Stress Disorder
Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective and reducing PTSD symptoms in veterans with chronic PTSD.
- Trial name
- NCT01211405
- Testing
- Low dose MDMA-assisted therapy, Medium dose MDMA-assisted therapy, Full dose MDMA-assisted therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Resilient Pharmaceuticals
Post-Traumatic Stress Disorder
A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder
This study is open to people aged 18 to 65 who have post-traumatic stress disorder. The purpose of this study is to find out whether a medicine called BI 1358894 improves symptoms in people with post-traumatic stress disorder.
- Trial name
- NCT05103657
- Testing
- BI 1358894
- Where
- 61 sites in United States, Croatia and 6 more
- Volunteers
- 318 people
- Sponsor
- Boehringer Ingelheim
Post Traumatic Stress Disorder
The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
The Safety and Tolerability of COMP360 in Participants with Post-traumatic Stress Disorder
- Trial name
- NCT05312151
- Testing
- Psilocybin
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 22 people
- Sponsor
- COMPASS Pathways
Inflammatory Bowel Diseases, Depressive Episode
Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
This study is a large population-based analysis in the United Kingdom (UK) using routine primary care data to investigate the impacts on quality-of-life outcomes and use of healthcare services in people aged 5 - 25 years…
- Conditions
- Inflammatory Bowel Diseases, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorder
- Trial name
- NCT05206734
- Testing
- No specific intervention
- Where
- United Kingdom
- Volunteers
- 19,469 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Stress Disorders, Post-Traumatic
Trial to Evaluate Efficacy of Magnetic Resonant Therapy (MRT) in PTSD
The purpose of this study is to establish the efficacy of Magnetic Resonant Therapy in treating Post Traumatic Stress Disorder in Veterans.
- Trial name
- NCT02268084
- Testing
- Magnetic EEG/ECG-guided Resonance Therapy
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Wave Neuroscience